Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma Source: Eur Respir J 2008; 31: 982-989 Year: 2008
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007
Problematic severe asthma Source: Eur Respir Mon 2012; 56: 22-39 Year: 2012
Asthma symptoms, SABA use, and lung function before and after a moderate or severe exacerbation Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Effect of montelukast on excessive airway narrowing in adult asthmatics not on controller therapy Source: Annual Congress 2006 - New developments in the treatment and management of asthma Year: 2006
The concept study: comparative influence of two treatment strategies on airway response to AMP Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Scientific rationale for using a single inhaler for asthma control Source: Eur Respir J 2007; 29: 587-595 Year: 2007
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002
Telithromycin for acute exacerbations of asthma: pulmonary function data from the TELICAST study Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005
Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015